The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EORTC CLTF 2021 | The CXCR4/CXCL12 axis as a potential therapeutic target in mycosis fungoides
Lilach Moyal, PhD, Tel Aviv University, Tel Aviv, Israel, explains how the CXCR4/CXCL12 axis was identified as a potential new target to treat mycosis fungoides (MF). Analysis of the tumor microenvironment showed that stromal fibroblasts secreted high levels of the CXCL12 chemokine, which is a ligand binding CXCR4. This receptor was also found to be overexpressed in MF, prompting experiments using a CXCR4 inhibitor, which showed that inhibiting this axis led to selective killing of lymphoma cells. This interview took place at the EORTC Cutaneous Lymphoma Group 20-21 meeting in Marseille.
